Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lykos Therapeutics
Biotech
Lykos still plotting path to approval for rejected MDMA therapy
“We continue to chart a path forward for an independent third-party review of prior phase 3 clinical data and an additional trial,” the company said.
James Waldron
Jan 17, 2025 9:00am
Lykos accepts FDA view that MDMA med needs new trial for approval
Oct 21, 2024 8:31am
Biopharma layoff rate stabilizes in Q3: Fierce Biotech analysis
Oct 4, 2024 3:50pm
BMS vet answers Foghorn’s call for CBO—Chutes & Ladders
Sep 6, 2024 8:30am
After FDA rejection and layoffs, Lykos' CEO is leaving
Sep 5, 2024 1:39pm
PharmAla launches tool aimed at easing access to MDMA drug info
Aug 28, 2024 12:55pm
